S-腺苷甲硫胺酸 SAMe × 肝臟健康

結論:證據支持但有警示

The case for SAMe and liver health is weak once the prescription drug ademetionine is separated from the consumer supplement.

C 🟠 C 薄弱證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

The case for SAMe and liver health is weak once the prescription drug ademetionine is separated from the consumer supplement. Examine grades a B for Liver Enzymes in chronic liver disease, but this is only a surrogate biomarker; every primary clinical liver endpoint scores lower (Cholestasis C, Bilirubin D, Liver Fibrosis D), and the 2015 meta-analysis it relies on found AST reduction but no significant ALT effect, with comparators UDCA and SNMC outperforming SAMe. The highest-quality evidence is negative: the 2006 Cochrane review and a 2011 double-blind RCT both show SAMe is no better than placebo in alcoholic liver disease, and for intrahepatic cholestasis of pregnancy UDCA is the preferred first-line agent. AASLD explicitly states human studies show no benefit of SAM supplementation on liver-related outcomes, while Mayo and Cleveland Clinic give only hedged, cautious statements. A grade C reflects limited surrogate-marker evidence with negative clinical-outcome data and no major-society endorsement of the supplement.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.44
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
75%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧/統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L5 臨床機構權威立場
0.29
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L11 AI 複核獨立判讀
0.50
L1 Examine國際基準
0.70
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.441
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

S-adenosyl-L-methionine for alcoholic liver diseases (Cochrane systematic review)
PMID: 16625556 2006 Cochrane SR n = 0
結論:The Cochrane review could not demonstrate any significant clinical effect of SAMe on the course of alcoholic liver disease; only one trial reported mortality and the result was not significant. Authors concluded SAMe should not be used for alcoholic liver disease outside randomized clinical trials.
🟢 高品質 學術資助 效應量:No significant effect on mortality or liver-related outcomes
前往 PubMed
S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial
PMID: 22044287 2011 隨機對照試驗 n = 37
結論:After 24 weeks, AST, ALT and bilirubin improved in the whole cohort, but there were no differences between SAMe and placebo in any clinical, biochemical or histological parameter. Improvements were attributed to alcohol abstinence rather than SAMe.
政府資助 效應量:No between-group difference; SAMe no more effective than placebo
前往 PubMed
S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis
PMID: 25774783 2015 統合分析 n = 705
結論:Across 11 RCTs (705 patients, seven types of chronic liver disease) SAMe significantly reduced TBIL and AST (AST MD -16.15, p=0.0003) but did not significantly improve ALT. Comparators UDCA and SNMC showed superior efficacy for certain conditions; safety was comparable to placebo.
政府資助 效應量:AST MD -16.15 (p=0.0003); ALT NS
前往 PubMed
Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review
PMID: 32184941 2020 系統性回顧 n = 1,791
結論:Across 9 trials (3 randomized, 6 non-randomized; 1791 patients) both placebo-controlled RCTs reported significant ALT reductions with ademetionine vs placebo within 2 weeks, with continued improvement through 8 weeks. One author was employed by Abbott, the manufacturer of the AdoMet product, raising a conflict-of-interest concern.
🟠 品質有限 ⚠️ 廠商資助 效應量:Significant ALT reduction within 2 weeks (RCT subset)
前往 PubMed
Meta-analysis of ursodeoxycholic acid and S-adenosylmethionine for improving the outcomes of intrahepatic cholestasis of pregnancy
PMID: 25173231 2014 統合分析 n = 0
結論:Meta-analysis of RCTs comparing UDCA, SAMe and combination therapy for intrahepatic cholestasis of pregnancy found UDCA more effective than SAMe on several outcomes; combination therapy offered some additional benefit. UDCA is the preferred first-line agent for ICP.
效應量:UDCA superior to SAMe on key ICP outcomes
前往 PubMed

L4a US FDA
謹慎
A lab-made form of SAMe is sold as a dietary supplement in the U.S., but SAMe has been sold as a prescription drug in parts of Europe for decades. 來源↗
L4b EU EFSA
未表態
— 本適應症無對應資料
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
從 1970 年代起,歐洲已廣泛使用 SAMe 來治療憂鬱症及其他生理狀況;1999 年美國則依《膳食補充劑健康與教育法》核准口服腸溶 SAMe 劑型,使消費者得於零售通路購買。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
謹慎
More studies are needed to determine whether SAMe is beneficial for people who have liver disease. 來源↗
L5c Cleveland Clinic
謹慎
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
反對

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

台灣社群對 SAMe 用於肝臟健康的真實討論,幾乎全集中在『毛小孩(犬貓)肝指數異常』面向,主要在 PTT dog 板與痞客邦寵物/獸醫部落格。飼主多在狗貓 ALT 飆高時,由獸醫建議併用 SAMe(沙美肝腦錠 Novifit/寶肝加強錠 Denamarin,常搭配 silybin 水飛薊),多人反映肝指數回降、精神食慾改善,但這些都屬個案、且常與其他治療並行,無法單獨歸因。相對地,『人類』自行補充 SAMe 護肝的鄉民實測心得非常稀少——人用 SAMe 的台灣討論多偏向憂鬱/關節,肝臟健康面向多由營養品部落格與電商業配頁帶出,非真正使用心得。故人用情境屬討論稀少,僅寵物情境有可觀且偏正面的軼事訊號。注意:社群經驗不可取代研究證據。

💬社群實感

分歧(寵物情境多數正面:飼主多反映犬貓肝指數回降、精神改善,惟多為個案且常併用其他治療;人類護肝情境幾無在地實測心得、無共識)

破解迷思 社群最常見的 4 個誤解
事實把寵物用的『沙美肝腦錠/寶肝加強錠』與人用 SAMe 補充品混為一談,認為劑量與用法可互通(劑型、劑量設計不同)
事實誤以為 SAMe 與水飛薊(奶薊草/silybin)是同一種『保肝成分』可互相取代,實際上是兩種不同機轉的成分(社群原 PO 也曾把兩者搞混)
事實把犬貓『肝指數回降』直接歸功於 SAMe 單一成分,忽略多半同時併用其他藥物與治療、且為個案經驗
事實誤以為人類可自行買 SAMe 當保肝品取代就醫,忽略肝病需醫師評估、社群/寵物經驗不能外推到人
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • 蘇活沙美肝腦錠 Novifit(法國維克 VIRBAC,犬貓用,S/M/L 劑量)
  • 寶肝加強錠 Denamarin(SAMe + silybin 水飛薊,犬貓用)
  • VetriScience SAMe Liver Health(犬貓用)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

NOW Foods, SAMe, 400 mg, 60 Tablets

代表來源 ↗
L10b · TFDA 法定身份 官方認定

S-腺苷甲硫氨酸據說對抑鬱、骨關節炎、膽汁淤積和肝功能異常的治療都有效;商品名稱包括思美泰/Transmetil。

來源 ↗

  • 戒酒或減少飲酒
  • 體重管理與代謝風險控制
  • 病毒性肝炎疫苗接種與篩檢
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v24 engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-s-adenosylmethionine-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-liver-health-INT-s-adenosylmethionine-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "S-腺苷甲硫胺酸能改善肝臟健康",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}